Pulmonary Arterial Hypertension (PAH) Market, By Drug Class (Prostacyclin and Analogs, SGC Stimulators, ERA and Phosphodiesterase-5) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025
108 Pages | Published Date : 12 / 11 / 18 | Report Code: AV199 | Report Format: PDF
The pulmonary arterial hypertension (PAH) market is estimated to represent a global market of USD 5.38 billion by 2017 with growth rate of 5.6%.
According to the World Health Organization (WHO), pulmonary arterial hypertension is a debilitating condition, characterized by the elevated pulmonary vascular resistance and pulmonary arterial pressure. The condition may lead to the failure of right ventricular or patient’s death. PAH can be hereditable, idiopathic, or associated with conditions such as congenital heart disease, connective tissue disease, hypertension, and HIV infection. PAH is categorized under rate disease as the prevalence of this disorder is very low, with an estimated prevalence around 15 to 50 cases per million population. However, the prevalence of this disorder is increasing during the past few years owing to the risk factors such as smoking, tobacco consumption, sedentary lifestyle, and other idiopathic conditions.
The market for Pulmonary Arterial Hypertension is primarily driven by the favourable government initiatives for the development of orphan drugs. The government provides benefits in terms of enhanced patent protection term, tax incentives etc. Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are the two important acts which facilitate the distribution and ethical usage of orphan therapeutics. For instance, The ODA facilitates tax credits up to 50.0% of overall research cost, protocol assistance, waiver in U.S. FDA fees and clinical tax incentives. This fact would, in turn, encourage key players to invest in this industry, augmenting the market growth to great extent.
Furthermore, growing awareness coupled with a well-planned reimbursement structure resulted in superlative diagnosis rate for PAH conditions across the globe, driving the industry growth. However, patent expiry of blockbuster therapeutics pulls back the industry growth to some extent. For instance, drugs such as Uptravi (2023), Orenitram (2024), and Opsumit are expired in near future. Additionally, this condition is often not diagnosed in a timely manner owing to its symptoms are subtle, and is confused with many other disease conditions. This fact would, in turn, further reduce the number of patients undergoing PAH treatment, hampering the market growth to some extent.
Drug Class Takeaway
In terms of drug class, the industry is categorized as Prostacyclin and Analogs, Soluble Guanylyl Cyclase (SGC) Stimulators, Endothelin receptor antagonist (ERA) and Phosphodiesterase-5. An ERA dominated the market with a substantial share of over 40% throughout the study period. On another hand, drugs targeting the prostacyclin pathway reported global sales of over USD 2.3 billion in 2017. Iloprost (Ventavis from Actelion), Epoprostenol (Veletri from Actelion and Flolan from GSK), Treprostinil (Tyvaso, Remodulin, and Orenitram from United Therapeutics) are some of the prostacyclin analogs approved by the U.S. FDA for the treatment of PAH. SGC stimulators are the lowest revenue generating drug class owing to the availability of other effective therapeutics.
Global Pulmonary Arterial Hypertension Market, by Drug Class, 2017 vs 2025
Geographically, the industry is categorized into North America, Europe, Asia Pacific and Rest of the World. Developed regions such as North America and Europe accounted for the highest share of the global market.
Key Vendor Takeaway
Companies such as Pfizer, Inc., GlaxoSmithKline, Novartis, Bayer, and Merck are some of the prominent participants in the global Pulmonary Arterial Hypertension market. Apart of it, the presence of small players is noticeable too. For instance, Actelion Pharmaceuticals is developing a Macitentan drug for pediatric PAH. The company has initiated phase III (titled as “Tomorrow”) study which will evaluate the effect of macitentan on children with PAH. Also, in October 2015, Gilead Sciences, Inc.’s new combination treatment of Tadalafil and Letairis is approved by the U.S. FDA. Such facts will further help key players to enhance their market presence.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2014 & 2016
- Base Year – 2017
- Estimated Year – 2018
- Projected Year – 2025
- Traders, Distributors, and Suppliers
- Government and Regional Agencies and Research Organizations
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY DRUG CLASS
- Prostacyclin and Analogs
- Soluble Guanylyl Cyclase (SGC) Stimulators
- Endothelin receptor antagonist (ERA)
MARKET, BY REGION
- North America
- Rest of Europe
- Asia Pacific
- Rest of APAC
- Rest of the World
- Middle East and Africa
- Latin America
1. PULMONARY ARTERIAL HYPERTENSION MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. PULMONARY ARTERIAL HYPERTENSION KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. PULMONARY ARTERIAL HYPERTENSION INDUSTRY STUDY
4.1. Porter’s Analysis
4.2. Market Attractiveness Analysis
4.3. Regulatory Framework Analysis
5. PULMONARY ARTERIAL HYPERTENSION MARKET LANDSCAPE
5.1. Market Share Analysis
6. PULMONARY ARTERIAL HYPERTENSION MARKET – BY DRUG CLASS
6.2. Prostacyclin and Analogs
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.3. Soluble Guanylyl Cyclase (SGC) Stimulators
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.4. Endothelin receptor antagonist (ERA)
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7. PULMONARY ARTERIAL HYPERTENSION MARKET– BY GEOGRAPHY
7.2. North America
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
18.104.22.168. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
22.214.171.124. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
126.96.36.199. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
188.8.131.52. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3.5. Rest of Europe
184.108.40.206. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4. Asia Pacific (APAC)
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
220.127.116.11. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
18.104.22.168. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4.5. Rest of APAC
22.214.171.124. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5. Rest of the World
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5.3. Latin America
126.96.36.199. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5.4. Middle East and Africa
188.8.131.52. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8. KEY VENDOR ANALYSIS
8.1. Pfizer, Inc.
8.1.1. Company Overview
8.1.2. SWOT Analysis
8.1.3. Key Developments
8.2.1. Company Overview
8.2.2. SWOT Analysis
8.2.3. Key Developments
8.3.1. Company Overview
8.3.2. SWOT Analysis
8.3.3. Key Developments
8.4.1. Company Overview
8.4.2. SWOT Analysis
8.4.3. Key Developments
8.5.1. Company Overview
8.5.2. SWOT Analysis
8.5.3. Key Developments
*Client can request additional company profiling as per specific requirements
9. 360 DEGREE ANALYSTVIEW
10.1. Research Methodology
10.4. Contact Us
List of Tables
Table 1 List of Acronyms
Table 2 Key Market Facts, 2014 – 2025
Table 3 Market Drivers: Impact Analysis
Table 4 Market Restraint: Impact Analysis
Table 5 Market Opportunity: Impact Analysis
Table 6 PEST Analysis
Table 7 Porter’s Five Forces Analysis
Table 8 Company Market Share Analysis
Table 9 Global Pulmonary Arterial Hypertension Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
Table 10 Pulmonary Arterial Hypertension Market, by Drug Class, 2014 – 2025 (USD Billion)
Table 11 Pulmonary Arterial Hypertension Market, by Geography, 2014 – 2025 (USD Billion)
Table 12 North America Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 13 U.S. Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 14 Canada Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 15 Europe Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 16 France Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 17 Germany Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 18 Asia Pacific Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 19 China Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 20 India Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 21 Latin America Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
Table 22 MEA Pulmonary Arterial Hypertension Market, 2014 – 2025 (USD Billion)
List of Figures
Figure 1 Research Methodology
Figure 2 Research Process Flow Chart
Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
Figure 4 Regulatory Framework Analysis
Figure 5 Pulmonary Arterial Hypertension Market, by Drug Class, 2014 – 2025 (USD Billion)
Figure 6 Pulmonary Arterial Hypertension Market, by Geography, 2014 – 2025 (USD Billion)
SCOPE AND OBJECTIVES
The objective of this report is to describe the market trends and revenue forecasts for the market for the upcoming years. The report focuses on defining and describing the key influencing factors for the growth of the market. It also offers an in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, key market players, and premium industry trends.
The report tracks the major market events including product launches, technological developments, mergers & acquisitions, and the innovative business strategies opted by key market players. Along with strategically analysing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities and challenges in the market. The scope of this report covers the market by its major segments.
KEY BENEFITS OF THE REPORT
• In-depth analysis of the key market dynamics
• Granular analysis of the current market scenario and expected factors to affect the market
• Detailed analysis of the geographic region, regional and county wise analysis
• Highlight on the strategies that are being adopted by the key players in this market to stay competitive
• Extensive analysis of the key players dominating the market
Research methodology is developed on a combination of specialist industry analyst knowledge and in-country research experience. We employ data interrogation methodologies to generate new and meaningful analyses and insights. The research study includes extensive use of secondary sources, paid databases (such as Bloomberg, Dun & Bradstreet, and BusinessWeek) and directories, to identify and collect information, useful to understand technical, commercial and market-oriented aspects. Market data and information are also collected (but not limited to) from the secondary sources such as:
- Official company’s website, financial and annual reporting
- Government statistical data
- Online publishing articles
- Industry player’s investor presentations
- Economic news articles
- National and international trade associations
- The financial, business, and mainstream press
- Industry study groups and semiofficial sources
- Informative channels related to the market topics
* Gathering data through secondary sources is only the first step. The ability to cross-refer market data through available secondary information often conflicting across multiple sources is a key aspect of the added value we provide
In order to verify and validate secondary market data, we engage with the Key Opinion Leaders (KoL’s), operating in the respective markets, through phone calls, emails, and web-based survey responses. This platform help us validate our data in terms of accuracy and gain insight into the current market and future expectations. Furthermore, the obtained information guide us to understand several facets of the market with respect to manufacturers and buyers’ perspectives.
In addition, to assign weights to all the relevant market dynamics and parameters and quantify their market impact for generating projected market growth rate, we used advanced machine learning algorithms in order to collate essential market data. The machine learning method utilizes algorithms such as regression, correlation, and decision tree, among others, to derive the desired output. This tool help us in deriving highly detailed forecasts, profound knowledge of product demand, and others.
These collected data points are carefully filtered, analyzed, compared, and presented in an easy way to develop accurate research study. Furthermore, all collected data is subjected to undergo exhaustive review process at country level, regional level, and global level.
Market forecast is primarily based on the year-on-year (YOY) growth rate. Data projection and future performance of each segment is analyzed based on the key aspects extracted from primary and secondary research results. Thus, data projection exhibits the assumption on how the market performs under microeconomic and macroeconomic parameters. Our market forecasting technique represents strategic conclusions which can play a crucial role for our client’s in making strategic marketing plans.
For forecasting, the following parameters were considered:
- Market drivers and restraints along with their current and expected impacts
- Technological scenario and expected developments
- Trends in the consumer behaviors
- End-user industry trends
We have assigned weights to above-mentioned parameters and quantified their market impacts using the weighted average analysis, to derive an expected market growth rate.
Once the information is collected, and the forecasts are determined, we provide a clear written analysis of the market conditions. This includes detailed information on market segments regarding market drivers, market restraints, and market opportunities. These offer insights on different channel dynamics, brand preference, incidence/prevalence data, consumption trend, and technology upgradations.
We also include supporting data from relevant awareness campaigns, new introductions, regulatory norms, government initiatives, and an industry player’s expansion in specific product segments. From a research perspective, this information explains and substantiates estimated data finding and forecast which helps us to improve the accuracy of the final report. This helps our clients to make better business decisions as they possess all the market information they require.
- The report provides the market in terms of USD million/billion at regional as well as country level
- We have implemented a mixture of top-down and bottom-up approach to estimate the total market and market for an individual segment
- We reviewed various publications from government and non-government organizations, analyst perspectives for different regions from the paid databases available to us
- This data helped us extract historical data and market scenario for various countries
- The total population of respective countries, end users, product demand, local presence of key players, and cost are considered to analyze market revenue
- Fundamental industry dynamics, demand-supply ratio, and upcoming technological trends are considered for the forecast period.
- Growth rates are estimated using correlation, regression, and time-series analysis
- All market estimates and forecasts have been validated through exhaustive primary research with key industry participants and analyst perspectives
We strive to become one of the trusted partner of our client by offering value added services and concrete research data.
From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round our client’s exact needs.
Our analyst aims to provide research studies in quickest turnaround time and in a much cost effective manner.
Data Accuracy and Reliability
We utilize a mix of primary, secondary research, and machine learning algorithms to generate accurate and comprehensive data about market size and revenue forecasts.
We offer most competitive pricing policy across the research industry
Why Choose Us
We devise research report with quality data:
Combined with an in-depth knowledge of the current industry and a sharp analytical mind, AnalystView serve our customer accurate research in accordance with a constantly evolving industry.
We work with businesses just like yours:
AnalystView committed to making a positive difference for our clients. This means whatever you demand, chances are we already have experience with something similar.